ELI LILLY AND COMPANY Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax
ELI LILLY AND COMPANY (LLY) had Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax of $4.10 million as of 2018-03-31, per its 10-Q filed 2018-04-27.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax · last filed 2018-04-27
- 2018-03-31: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $4.10M.
- 2017-12-31: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $184.70M.
- 2017-09-30: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $259.70M.
- 2017-06-30: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $247.50M.
| Period end | Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax |
|---|---|
| 2018-03-31 | $4.10M 10-Q · filed 2018-04-27 |
| 2017-12-31 | $184.70M 10-Q · filed 2018-04-27 |
| 2017-09-30 | $259.70M 10-Q · filed 2017-10-27 |
| 2017-06-30 | $247.50M 10-Q · filed 2017-07-28 |
| 2017-03-31 | $280.50M 10-Q · filed 2017-05-01 |
| 2016-12-31 | $352.60M 10-K · filed 2018-02-20 |
| 2016-09-30 | $138.80M 10-Q · filed 2016-10-28 |
| 2016-06-30 | $79.80M 10-Q · filed 2016-07-28 |
| 2016-03-31 | $69.50M 10-Q · filed 2016-04-29 |
| 2015-12-31 | $68.00M 10-K · filed 2017-02-21 |
| 2014-12-31 | $171.90M 10-K · filed 2016-02-19 |
| 2013-12-31 | $375.60M 10-K · filed 2015-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |